475 related articles for article (PubMed ID: 26573511)
1. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.
Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J
J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.
Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J
World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine-labeled anti-epidermal growth factor receptor binding bovine serum albumin-polycaprolactone for targeting imaging of glioblastoma.
Li C; Tan J; Chang J; Li W; Liu Z; Li N; Ji Y
Oncol Rep; 2017 Nov; 38(5):2919-2926. PubMed ID: 28901480
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Effect of Nanoparticle
Ming H; Fang L; Gao J; Li C; Ji Y; Shen Y; Hu Y; Li N; Chang J; Li W; Tan J
AJR Am J Roentgenol; 2017 May; 208(5):1116-1126. PubMed ID: 28301223
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells.
Maya S; Kumar LG; Sarmento B; Sanoj Rejinold N; Menon D; Nair SV; Jayakumar R
Carbohydr Polym; 2013 Apr; 93(2):661-9. PubMed ID: 23499109
[TBL] [Abstract][Full Text] [Related]
6. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
8. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts.
Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R
Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568
[TBL] [Abstract][Full Text] [Related]
10. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
Jung KH; Choe YS; Paik JY; Lee KH
J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide.
Liao C; Sun Q; Liang B; Shen J; Shuai X
Eur J Radiol; 2011 Dec; 80(3):699-705. PubMed ID: 20810233
[TBL] [Abstract][Full Text] [Related]
16. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
18. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
[TBL] [Abstract][Full Text] [Related]
19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
20. Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.
Chen HL; Hsu FT; Kao YJ; Liu HS; Huang WZ; Lu CF; Tsai PH; Ali AAA; Lee GA; Chen RJ; Chen CY
J Nanobiotechnology; 2017 Nov; 15(1):86. PubMed ID: 29166921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
